Wedbush Forecasts Lower Earnings for Dianthus Therapeutics

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Equities researchers at Wedbush lowered their Q1 2025 earnings estimates for shares of Dianthus Therapeutics in a research note issued to investors on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.74) for the quarter, down from their previous forecast of ($0.62). Wedbush currently has a “Outperform” rating and a $36.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. Wedbush also issued estimates for Dianthus Therapeutics’ Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($3.11) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($3.38) EPS, FY2028 earnings at ($2.75) EPS and FY2029 earnings at $1.79 EPS.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%.

DNTH has been the topic of a number of other research reports. TD Cowen began coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday. Finally, Guggenheim reiterated a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $52.14.

Dianthus Therapeutics Trading Up 0.2 %

NASDAQ:DNTH opened at $21.33 on Friday. The stock has a market capitalization of $631.30 million, a PE ratio of -8.53 and a beta of 1.82. The firm’s 50 day moving average is $22.61 and its 200 day moving average is $24.92. Dianthus Therapeutics has a 12 month low of $18.13 and a 12 month high of $33.77.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. MetLife Investment Management LLC grew its position in shares of Dianthus Therapeutics by 3.1% during the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock valued at $313,000 after purchasing an additional 433 shares in the last quarter. Invesco Ltd. grew its position in shares of Dianthus Therapeutics by 7.4% during the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock valued at $251,000 after purchasing an additional 790 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after purchasing an additional 814 shares in the last quarter. Barclays PLC grew its position in shares of Dianthus Therapeutics by 2.6% during the 4th quarter. Barclays PLC now owns 42,766 shares of the company’s stock valued at $933,000 after purchasing an additional 1,082 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Dianthus Therapeutics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock valued at $3,641,000 after purchasing an additional 1,092 shares in the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.